Financial reports
20-F
2023 FY
Annual report (foreign)
28 Mar 24
20-F
2022 FY
Annual report (foreign)
23 Mar 23
20-F
2021 FY
Annual report (foreign)
24 Mar 22
20-F
2020 FY
Annual report (foreign)
25 Mar 21
20-F
2019 FY
Annual report (foreign)
27 Mar 20
20-F
2018 FY
Annual report (foreign)
29 Mar 19
20-F
2017 FY
Annual report (foreign)
23 Mar 18
20-F
2016 FY
Annual report (foreign)
23 Mar 17
20-F
2015 FY
Annual report (foreign)
25 Mar 16
ARS
2006 FY
Annual report to shareholders
14 Nov 07
Current reports
6-K
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
8 Apr 24
6-K
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
29 Mar 24
6-K
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
29 Mar 24
6-K
Galapagos announces full year 2023 results and outlook for 2024
23 Feb 24
6-K
Galapagos presents at EBMT-EHA annual meeting 2024
16 Feb 24
6-K
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6 Feb 24
6-K
Current report (foreign)
4 Jan 24
6-K
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4 Jan 24
6-K
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4 Jan 24
6-K
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
21 Dec 23
Registration and prospectus
S-8
Registration of securities for employees
4 Dec 23
S-8
Registration of securities for employees
12 Dec 22
S-8
Registration of securities for employees
26 Oct 21
S-8
Registration of securities for employees
9 Oct 20
S-8
Registration of securities for employees
24 May 19
F-3ASR
Automatic shelf registration (foreign)
29 Mar 19
424B3
Prospectus supplement
15 Oct 18
424B5
Prospectus supplement for primary offering
14 Sep 18
424B5
Prospectus supplement for primary offering
13 Sep 18
S-8
Registration of securities for employees
29 May 18
Proxies
No filings
Other
UPLOAD
Letter from SEC
2 Oct 17
CORRESP
Correspondence with SEC
13 Sep 17
UPLOAD
Letter from SEC
5 Sep 17
CORRESP
Correspondence with SEC
16 Aug 17
UPLOAD
Letter from SEC
2 Aug 17
CT ORDER
Confidential treatment order
27 Jul 16
CT ORDER
Confidential treatment order
19 Feb 16
CT ORDER
Confidential treatment order
6 Jul 15
EFFECT
Notice of effectiveness
13 May 15
UPLOAD
Letter from SEC
12 May 15
Ownership
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
EcoR1 Capital, LLC
7 Jun 23
SC 13G/A
EcoR1 Capital, LLC
14 Feb 23
SC 13G
FMR LLC
9 Feb 23
SC 13G
EcoR1 Capital, LLC
3 Feb 22
SC 13D
VAN HERK INVESTMENTS B.V.
2 Nov 21
SC 13G/A
Capital International Investors
10 May 21
SC 13G/A
Capital International Investors
10 Feb 21
SC 13G
Capital International Investors
10 Feb 21